https://www.selleckchem.com/products/gw4869.html
Aim Multicenter study to investigate the safety of mite extract product Novo-Helisen Depot, Strengths 1 to 3 (NHD3), as subcutaneous immunotherapy (SCIT), in Chinese children and adolescents with allergic rhinitis (AR) and allergic asthma (AA). Patients methods We evaluated SCIT-related adverse events (AEs) during NHD3 14-week initial therapy in children (5-11 years) and adolescents (12-17 years) with perennial symptomatic AR and AA. Results Among 3600 injections in 250 patients, 361/3600 (10.0%) injections caused SCIT-related AEs
Like
Comment
Share
